Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis
Authors:
- Rebecca AndersonRARebecca Anderson
- Angels FranchAFAngels Franch
- Margarida CastellMargarida Castell
- Francisco J Perez-CanoFrancisco J Perez-Cano
- Rolf BräuerRBRolf Bräuer
- Dirk PohlersDPDirk Pohlers
- Mieczyslaw GajdaMGMieczyslaw Gajda
- Alexandros P SiskosASAlexandros P Siskos
- Theodora KatsilaTKTheodora Katsila
- Constantin TamvakopoulosCTConstantin Tamvakopoulos
- Una RauchhausURUna Rauchhaus
- Steffen PanznerSPSteffen Panzner
Open Access
- 19 July 2010
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 12 (4) , R147
Abstract
Introduction: The objective of this study was to evaluate the efficacy of intravenous (i.v.) injection of liposomally encapsulated dexamethasone phosphate (DxM-P) in comparison to free DxM-P in rats with established adjuvant arthritis (AA). This study focused on polyethylene glycol (PEG)-free liposomes, to minimize known allergic reactions caused by neutral PEG-modified (PEG-ylated) liposomes.Methods: Efficacy was assessed clinically and histologically using standard scores. Non-specific and specific immune parameters were monitored. Activation of peritoneal macrophages was analyzedviacytokine profiling. Pharmacokinetics/biodistribution of DxM in plasma, synovial membrane, spleen and liver were assessedviamass spectrometry.Results: Liposomal DxM-P (3 × 1 mg/kg body weight; administered intravenously (i.v.) on Days 14, 15 and 16 of AA) suppressed established AA, including histological signs, erythrocyte sedimentation rate, white blood cell count, circulating anti-mycobacterial IgG, and production of interleukin-1beta (IL-1β) and IL-6 by peritoneal macrophages. The suppression was strong and long-lasting. The clinical effects of liposomal DxM-P were dose-dependent for dosages between 0.01 and 1.0 mg/kg. Single administration of 1 mg/kg liposomal DxM-P and 3 × 1 mg/kg of free DxM-P showed comparable effects consisting of a partial and transient suppression. Moreover, the effects of medium-dose liposomal DxM-P (3 × 0.1 mg/kg) were equal (in the short term) or superior (in the long term) to those of high-dose free DxM-P (3 × 1 mg/kg), suggesting a potential dose reduction by a factor between 3 and 10 by liposomal encapsulation. For at least 48 hours after the last injection, the liposomal drug achieved significantly higher levels in plasma, synovial membrane, spleen and liver than the free drug.Conclusions: This new PEG-free formulation of macrophage-targeting liposomal DxM-P considerably reduces the dose and/or frequency required to treat AA, with a potential to enhance or prolong therapeutic efficacy and limit side-effects also in the therapy of rheumatoid arthritis. Depot and/or recirculation effects in plasma, inflamed joint, liver, and spleen may contribute to this superiority of liposomally encapsulated DxM-P.Keywords
This publication has 48 references indexed in Scilit:
- Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatmentArthritis Research & Therapy, 2009
- Amphipathic weak acid glucocorticoid prodrugs remote‐loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: A novel approach to treating autoimmune arthritisArthritis & Rheumatism, 2007
- Cells of the synovium in rheumatoid arthritis. MacrophagesArthritis Research & Therapy, 2007
- High throughput HPLC-ESI-MS method for the quantitation of dexamethasone in blood plasmaJournal of Pharmaceutical and Biomedical Analysis, 2007
- Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomesArthritis & Rheumatism, 2002
- Pharmacokinetics and Pharmacodynamics of Dexamethasone Sodium‐m‐Sulfobenzoate (DS) after Intravenous and Intramuscular Administration: A Comparison with Dexamethasone Phosphate (DP)The Journal of Clinical Pharmacology, 2001
- Elevated cytokine messenger RNA levels in the peripheral blood of patients with rheumatoid arthritis suggest different degrees of myeloid cell activationArthritis & Rheumatism, 1997
- Unbedenklichkeitsaspekte bei der Anwendung von pegyliertem liposomalem Doxorubicin bei KrebspatientenDrugs, 1997
- Inorganic and organic phosphate measurements in the nanomolar rangeAnalytical Biochemistry, 1987
- An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoidsJournal of Ultrastructure Research, 1970